Successes and challenges in the development of BD1-selective BET inhibitors: a patent review

References

• Sanchez R, Meslamani J, Zhou MM. The bromodomain: from epigenome reader to druggable target. Biochim Biophys Acta. 2014 Aug;1839(8):676–85. doi: 10.1016/j.bbagrm.2014.03.011
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149(1):214–31. doi: 10.1016/j.cell.2012.02.013
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Knapp S. The bromodomain interaction module. FEBS Lett. 2012 Aug 14;586(17):2692–704. doi: 10.1016/j.febslet.2012.04.045
   PubMed Web of Science ®Google Scholar
• Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem. 2007;282(18):13141–5. doi: 10.1074/jbc.R700001200
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zeng L, Shen C, et al. Structural mechanism of transcriptional regulator NSD3 recognition by the ET domain of BRD4. Structure. 2016 Jul 6;24(7):1201–8. doi: 10.1016/j.str.2016.04.019
   PubMed Web of Science ®Google Scholar
• Hsu SC, Gilgenast TG, Bartman CR, et al. The BET protein BRD2 cooperates with CTCF to enforce transcriptional and architectural boundaries. Mol Cell. 2017;66(1):102–116.e7. doi: 10.1016/j.molcel.2017.02.027
   PubMed Web of Science ®Google Scholar
• Wessel SR, Mohni KN, Luzwick JW, et al. Functional analysis of the replication fork proteome identifies BET proteins as PCNA regulators. Cell Rep. 2019;28(13):3497–3509.e4. doi: 10.1016/j.celrep.2019.08.051
   PubMed Web of Science ®Google Scholar
• Kim JJ, Lee SY, Gong F, et al. Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity. Genes Dev. 2019;33(23–24):1751–74. doi: 10.1101/gad.331231.119
   PubMed Web of Science ®Google Scholar
• Li X, Baek G, Ramanand SG, et al. BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer. Cell Rep. 2018;22(3):796–808. doi: 10.1016/j.celrep.2017.12.078
   PubMed Web of Science ®Google Scholar
• Shang E, Nickerson HD, Wen D, et al. The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation. Development. 2007;134(19):3507–15. doi: 10.1242/dev.004481
   PubMed Web of Science ®Google Scholar
• Stonestrom AJ, Hsu SC, Jahn KS, et al. Functions of BET proteins in erythroid gene expression. Blood. 2015;125(18):2825–34. doi: 10.1182/blood-2014-10-607309
   PubMed Web of Science ®Google Scholar
• Zaware N, Zhou MM. Bromodomain biology and drug discovery. Nat Struct Mol Biol. 2019;26(10):870–9.
   PubMed Web of Science ®Google Scholar
• Gyuris A, Donovan DJ, Seymour KA, et al. The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis. Biochim Biophys Acta - Gene Regul Mecha. 2009;1789(5):413–421. doi: 10.1016/j.bbagrm.2009.03.005
   PubMed Web of Science ®Google Scholar
• Velíšek L, Shang E, Velíšková J, et al. GABAergic neuron deficit as an idiopathic generalized epilepsy mechanism: The role of BRD2 haploinsufficiency in juvenile myoclonic epilepsy. PLoS One. 2011;6(8):e23656. doi: 10.1371/journal.pone.0023656
   PubMed Web of Science ®Google Scholar
• Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol. 2013;190(7):3670–8. doi: 10.4049/jimmunol.1202838
   PubMed Web of Science ®Google Scholar
• Wang F, Liu H, Blanton WP, et al. Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem J. 2010;425(1):71–83. doi: 10.1042/BJ20090928
   Web of Science ®Google Scholar
• Jones MH, Numata M, Shimane M. Identification and characterization of BRDT: a testis-specific gene related to the bromodomain genes RING3 and drosophila fsh. Genomics. 1997;45(3):529–534. doi: 10.1006/geno.1997.5000
   PubMed Web of Science ®Google Scholar
• Gaucher J, Boussouar F, Montellier E, et al. Bromodomain-dependent stage-specific male genome programming by BRDT. EMBO J. 2012;31(19):3809–20. doi: 10.1038/emboj.2012.233
   PubMed Web of Science ®Google Scholar
• Pivot-Pajot C, Caron C, Govin J, et al. Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol Cell Biol. 2003;23(15):5354–65. doi: 10.1128/MCB.23.15.5354-5365.2003
   PubMed Web of Science ®Google Scholar
• Lamonica JM, Deng W, Kadauke S, et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci, USA. 2011;108(22):E159–68. doi: 10.1073/pnas.1102140108
   PubMed Web of Science ®Google Scholar
• Lee JE, Park YK, Park S, et al. Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis. Nat Commun. 2017;8(1). doi: 10.1038/s41467-017-02403-5
   Google Scholar
• Bao Y, Wu X, Chen J, et al. Brd4 modulates the innate immune response through Mnk2-eIF4E pathway-dependent translational control of IkappaBalpha. Proc Natl Acad Sci, USA. 2017 May 16;114(20):E3993–E4001, doi: 10.1073/pnas.1700109114
   PubMed Web of Science ®Google Scholar
• Korb E, Herre M, Zucker-Scharff I, et al. BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice. Nat Neurosci. 2015;18(10):1464–73. doi: 10.1038/nn.4095
   PubMed Web of Science ®Google Scholar
• Cheung KL, Zhang F, Jaganathan A, et al. Distinct roles of Brd2 and Brd4 in potentiating the transcriptional program for Th17 cell differentiation. Mol Cell. 2017 Mar 16;65(6):1068–1080.e5. doi: 10.1016/j.molcel.2016.12.022
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ma P, Jing Y, et al. BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1. Theranostics. 2016;6(2):219–30. doi: 10.7150/thno.13178
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017;18(4):246–62. doi: 10.1038/nrm.2016.143
   PubMed Web of Science ®Google Scholar
• French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003 Jan 15;63(2):304–7.
   PubMed Web of Science ®Google Scholar
• Da Costa D, Agathanggelou A, Perry T, et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013 Jul 19;3(7):e126. doi: 10.1038/bcj.2013.24
   PubMedGoogle Scholar
• Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013 Apr 11;153(2):320–34. doi: 10.1016/j.cell.2013.03.036
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–33. doi: 10.1038/nature10509
   PubMed Web of Science ®Google Scholar
• Schaefer U. Pharmacological inhibition of bromodomain-containing proteins in inflammation. Cold Spring Harb Perspect Biol. 2014 Jun 2;6(6):a018671–a018671.
   PubMed Web of Science ®Google Scholar
• Mills RJ, Humphrey SJ, Fortuna PRJ, et al. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell. 2021;184(8):2167–82.e22. doi: 10.1016/j.cell.2021.03.026
   PubMed Web of Science ®Google Scholar
• Boehm D, Conrad RJ, Ott M. Bromodomain proteins in HIV infection. Viruses. 2013 Jun 21;5(6):1571–86.
   PubMed Web of Science ®Google Scholar
• Segatto M, Fittipaldi R, Pin F, et al. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. Nat Commun. 2017 Nov 22;8(1):1707. doi: 10.1038/s41467-017-01645-7
   PubMedGoogle Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–73. doi: 10.1038/nature09504
   PubMed Web of Science ®Google Scholar
• Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119–23. doi: 10.1038/nature09589
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S, Herbschleb K, Massard C, et al. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. Eur J Cancer. 2019;109:103–10. doi: 10.1016/j.ejca.2018.12.020
   PubMed Web of Science ®Google Scholar
• Dey A, Chitsaz F, Abbasi A, et al. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci, USA. 2003 Jul 22;100(15):8758–63. doi: 10.1073/pnas.1433065100
   PubMed Web of Science ®Google Scholar
• Gamsjaeger R, Webb SR, Lamonica JM, et al. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol Cell Biol. 2011;31(13):2632–40. doi: 10.1128/MCB.05413-11
   PubMed Web of Science ®Google Scholar
• Moriniere J, Rousseaux S, Steuerwald U, et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature. 2009 Oct 1;461(7264):664–8. doi: 10.1038/nature08397
   PubMed Web of Science ®Google Scholar
• Gilan O, Rioja I, Knezevic K, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368(6489):387–94. doi: 10.1126/science.aaz8455
   PubMed Web of Science ®Google Scholar
• Meslamani J, Smith SG, Sanchez R, et al. Structural features and inhibitors of bromodomains [review]. Drug Discov Today Technol. 2016;19:3–15. doi: 10.1016/j.ddtec.2016.09.001
   PubMedGoogle Scholar
• Watson RJ, Bamborough P, Barnett H, et al. GSK789: a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins. J Med Chem. 2020;63(17):9045–69. doi: 10.1021/acs.jmedchem.0c00614
   PubMed Web of Science ®Google Scholar
• Picaud S, Wells C, Felletar I, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci, USA. 2013;110(49):19754–9. doi: 10.1073/pnas.1310658110
   PubMed Web of Science ®Google Scholar
• Mujtaba S, Zeng L, Zhou MM. Structure and acetyl-lysine recognition of the bromodomain. Oncogene. 2007 Aug 13;26(37):5521–7.
   PubMed Web of Science ®Google Scholar
• Lloyd JT, Glass KC. Biological function and histone recognition of family IV bromodomain-containing proteins. J Cell Physiol. 2018 Mar;233(3):1877–86. doi: 10.1002/jcp.26010
   PubMed Web of Science ®Google Scholar
• Gacias M, Gerona-Navarro G, Plotnikov AN, et al. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. Chem Biol. 2014;21(7):841–54. doi: 10.1016/j.chembiol.2014.05.009
   PubMedGoogle Scholar
• Xue X, Zhang Y, Liu Z, et al. Discovery of Benzo[cd]indol-2(1H)-ones as potent and specific BET bromodomain inhibitors: structure-based virtual screening. Optimization, and biological evaluation. J Med Chem. 2016;59(4):1565–1579. doi: 10.1021/acs.jmedchem.5b01511
   PubMed Web of Science ®Google Scholar
• Jiang F, Hu Q, Zhang Z, et al. Discovery of Benzo[cd]indol-2(1 H)-ones and Pyrrolo[4,3,2- de]quinolin-2(1 H)-ones as Bromodomain and extra-terminal domain (BET) inhibitors with selectivity for the first Bromodomain with potential high efficiency against Acute Gouty Arthritis. J Med Chem. 2019;62(24):11080–11107. doi: 10.1021/acs.jmedchem.9b01010
   PubMed Web of Science ®Google Scholar
• Raux B, Voitovich Y, Derviaux C, et al. Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins. J Med Chem. 2016 Feb 25;59(4):1634–41. doi: 10.1021/acs.jmedchem.5b01708
   PubMed Web of Science ®Google Scholar
• Cheung K, Lu G, Sharma R, et al. BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice. Proc Natl Acad Sci USA. 2017;114(11):2952–7. doi: 10.1073/pnas.1615601114
   PubMed Web of Science ®Google Scholar
• Cui H, Divakaran A, Pandey AK, et al. Selective N-terminal BET bromodomain inhibitors by targeting non-conserved residues and structured water displacement. Angew Chem Int Ed. 2021;60(3):1220–6. doi: 10.1002/anie.202008625
   PubMed Web of Science ®Google Scholar
• Divakaran A, Talluri SK, Ayoub AM, et al. Molecular basis for the N-Terminal bromodomain-and-extra-terminal-family selectivity of a dual kinase-bromodomain Inhibitor. J Med Chem. 2018;61(20):9316–9334. doi: 10.1021/acs.jmedchem.8b01248
   PubMed Web of Science ®Google Scholar
• Ma J, Chen H, Yang J, et al. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors. Bioorg Med Chem. 2019;27(9):1871–81. doi: 10.1016/j.bmc.2019.03.037
   PubMed Web of Science ®Google Scholar
• Zhang G, Plotnikov AN, Rusinova E, et al. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J Med Chem. 2013;56(22):9251–64. doi: 10.1021/jm401334s
   PubMed Web of Science ®Google Scholar
• Cipriano A, Milite C, Feoli A, et al. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and extra-terminal domain (BET) inhibitors with selectivity for the first Bromodomain. ChemMedchem. 2022 Oct 19;17(20):e202200343. doi: 10.1002/cmdc.202200343
   PubMed Web of Science ®Google Scholar
• Zerio CJ, Sivinski J, Wijeratne EMK, et al. Physachenolide C is a potent, selective BET inhibitor. J Med Chem. 2023 Jan 12;66(1):913–33. doi: 10.1021/acs.jmedchem.2c01770
   PubMed Web of Science ®Google Scholar
• Modukuri RK, Yu Z, Tan Z, et al. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. Proc Natl Acad Sci, USA. 2022 May 31;119(22):e2122506119. doi: 10.1073/pnas.2122506119
   PubMed Web of Science ®Google Scholar
• Amans D, Bamborough P, Bit RA, et al., inventors; GlaxoSmithKline LLC, assignee. Preparation of thieno[3,2-c]pyridin-4(5H)-ones useful as BET inhibitors patent WO2014078257. 2014.
   Google Scholar
• Amans D, Bamborough P, Barker MD, et al., inventors. GlaxoSmithKline Intellectual Property (No.2) limited, assignee. Preparation of furopyridines as bromodomain inhibitors useful in treating cancer, inflammation, and autoimmune disorders patent WO2014140077, 2014. doi: 10.1039/c3cp53748j
   Google Scholar
• Bair KW, Herbertz T, Kauffman GS, et al., inventors; FORMA Therapeutics, Inc., assignee. Tetrahydroquinoline compositions as BET bromodomain inhibitors and their preparation patent US20160256448, 2016.
   Google Scholar
• Bair KW, Herbertz T, Kauffman GS, et al., inventors; FORMA Therapeutics, Inc., assignee. Benzopiperazine compositions as BET bromodomain inhibitors and their preparation patent US20160256458, 2016.
   Google Scholar
• Brown SD, Coburn CA, Kharenko O, inventors; Zenith Epigenetics Corp., assignee. Preparation of substituted imidazolyl triazoles as BET protein inhibitors via binding to bromodomains useful in therapy patent WO2016092375, 2016.
   Google Scholar
• Morelli X, Combes S, Guillemot J-C, et al., inventors; INSERM (Institut National de la Sante et de la Recherche Medicale) Centre National de la Recherche Scientifique (CNRS) Universite d’Aix-Marseille Institut Jean Paoli & Irene Calmettes, assignee. Preparation of xanthine derivatives as inhibitors of BET proteins for the treatment of cancer and other diseases patent WO2017114843, 2017.
   Google Scholar
• Betzi S, Combes S, Collette Y, et al., inventors; Centre National de la Recherche Scientifique Universite d’Aix-Marseille Institut National de la Sante et de la Recherche Medicale (INSERM), assignee. Preparation of substituted xanthines as inhibitors of the bromodomains of BET proteins such as Brd4 for potential use in the treatment of diseases such as cancer patent WO2019086712, 2019.
   Google Scholar
• Zhou J, Brasier AR, Tian B, et al., inventors. 3,4-Dihydroquinolin-2(1H)-ones as inhibitors of bromodomain-containing protein 4 (BRD4) and their preparation patent WO2018112037, 2018.
   Google Scholar
• Wang S, Hu J, Xu F, inventors; The Regents of the University of Michigan, assignee. Fused 1,4-diazepines as BET bromodomain inhibitors and their preparation patent WO2018144789, 2018.
   Google Scholar
• Abbineni C, Linnanen T, Mukherjee S, et al., inventors; Orion Corporation, assignee. Preparation of the bromodomain inhibitors and their application as medical use patent WO2018109271, 2018.
   Google Scholar
• Albert Ludwig Universitaet Freiburg, assignee. Preparation of fused pyrroles such as cycloheptapyrrolones as inhibitors of bromodomain proteins patent WO2020127846, 2020.
   Google Scholar
• Vadivelu S, Rajagopal S, Gondrala PK, et al., inventors; Jubilant Biosys Limited, assignee. Preparation of tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer patent WO2016157221, 2016.
   Google Scholar
• Vadivelu S, Rajagopal S, Ramaiah MM, et al., inventors; Jubilant Biosys Limited, assignee. Preparation of tricyclic fused pyridin-2-one derivatives as BRD4 inhibitors for treatment of proliferative disorders and cancer patent WO2017042834, 2017.
   Google Scholar
• Fang H, Zhou W, Hu S, et al., inventors; Jacobio-Beta Pharmaceuticals Co., Ltd. Jacobio-Alpha Pharmaceuticals Co., Ltd. Jacobio Pharmaceuticals Co., Ltd., assignee. Novel tricyclic compounds as bromodomain and BET inhibitors and their preparation patent WO2019080941, 2019.
   Google Scholar
• Fang H, Chen M, Yang G, et al., inventors; Jacobio-Beta Pharmaceuticals Co., Ltd. Jacobio Pharmaceuticals Co., Ltd., assignee. Preparation of tricyclic compounds as bromodomain and BET inhibitors patent WO2020001152, 2020.
   Google Scholar
• Han Y, Li D, Long H, et al., inventors; Jingrui Biopharma Co., Ltd., assignee. Preparation of tricyclic compounds that are bromodomain inhibitors as anticancer agents patent WO2022156757, 2022
   Google Scholar
• Oh S-S, Choi M, inventors; Kainos Medicine, Inc., assignee. Benzotriazolodiazepine derivatives as bromodomain-inhibiting compounds and their preparation and use for the treatment of cancer patent WO2015156601, 2015.
   Google Scholar
• Bradner JE, Tanaka M, Buckley D, et al., inventors; Dana-Farber Cancer Institute, Inc., assignee. Preparation of cyanothienotriazolodiazepine derivatives for use as bromodomain inhibitors patent WO2017044849, 2017.
   Google Scholar
• Engelhardt H, inventor; Boehringer Ingelheim International GmbH, assignee. Benzimidazole derivatives as BRD4 inhibitors and their preparation and use for the treatment of cancer patent WO2015169962, 2015.
   Google Scholar
• Duffy BC, Liu S, Quinn JF, et al., inventors; Zenith Epigenetics Corp., assignee. Preparation of azabicyclic compounds as BET inhibitors and therapeutic uses thereof patent WO2015002754, 2015.
   Google Scholar
• Liu S, Quinn JF, Duffy BC, et al., inventors; Zenith Epigenetics Corp., assignee. Preparation of azabicyclic compounds as BET inhibitors and therapeutic uses thereof patent WO2015004533, 2015.
   Google Scholar
• Pourashraf M, Jacquemot G, Claridge S, et al., inventors; NEOMED Institute, assignee. Substituted benzimidazoles as bromodomain inhibitors, their preparation and their use as pharmaceuticals patent WO2017024412, 2017.
   Google Scholar
• Fairfax DJ, Martin GS, Quinn JF, et al., inventors; RVX Therapeutics Inc. Zenith Epigenetics Ltd., assignee. Preparation of biaryl compounds as BET inhibitors for treatment of cancer, autoimmune disorders, and other diseases patent US20140140956, 2014.
   Google Scholar
• Engelhardt H, inventor; Boehringer Ingelheim International GmbH, assignee. Preparation of triazolopyrazine derivatives as BRD4 inhibitors patent WO2015067770, 2015.
   Google Scholar
• Jiang MX, Molino BF, Liu S, et al., inventors; Zenith Epigenetics Corp., assignee. Preparation of 5-(3,5-dialkylisoxazol-4-yl)pyridinones as bromodomain inhibitors patent WO2016087936. 2016.
   Google Scholar
• Jacquemot G, Bayrakdarian M, Johnstone S, et al., inventors; NEOMED Institute, assignee. Preparation of aryl-substituted dihydroquinolinones as bromodomain inhibitors patent WO2017024408, 2017.
   Google Scholar
• Brown SD, Kharenko O, inventors; Zenith Epigenetics Ltd., assignee. Preparation of 1H-imidazo[4,5-b]pyridine and 2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine heterocyclic compounds useful as BET bromodomain inhibitors patent WO2017103670, 2017.
   Google Scholar
• Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200.
   PubMed Web of Science ®Google Scholar
• Zengerle M, Chan K-H, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015;10(8):1770–7. doi: 10.1021/acschembio.5b00216
   PubMed Web of Science ®Google Scholar
• Zhou B, Hu J, Xu F, et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2018;61(2):462–81. doi: 10.1021/acs.jmedchem.6b01816
   PubMed Web of Science ®Google Scholar
• Shi C, Zhang H, Wang P, et al. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis. Cell Death Dis. 2019;10(11):1–11. doi: 10.1038/s41419-019-2022-2
   Google Scholar
• Raina K, Lu J, Qian Y, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci, USA. 2016;113(26):7124–9. doi: 10.1073/pnas.1521738113
   PubMed Web of Science ®Google Scholar
• Cipriano A, Sbardella G, Ciulli A. Targeting epigenetic reader domains by chemical biology. Curr Opin Chem Biol. 2020;57:82–94. doi: 10.1016/j.cbpa.2020.05.006
   PubMed Web of Science ®Google Scholar
• Gopalsamy A. Selectivity through targeted protein degradation (TPD). J Med Chem. 2022;65(12):8113–26. doi: 10.1021/acs.jmedchem.2c00397
   PubMed Web of Science ®Google Scholar
• Guenette RG, Yang SW, Min J, et al. Target and tissue selectivity of PROTAC degraders. Chem Soc Rev. 2022;51(14):5740–56. doi: 10.1039/D2CS00200K
   PubMed Web of Science ®Google Scholar
• Siegel S, Cromm P, Haendler B, et al., inventors; Bayer Aktiengesellschaft, assignee. Preparation of substituted 2,3-benzodiazepines derivatives as BET inhibitors and degraders for treatment of hyperproliferative diseases patent WO2021152113, 2021.
   Google Scholar
• Siegel S, Baeurle S, Cleve A, et al., inventors; Bayer Pharma Aktiengesellschaft, assignee. 2,3-benzodiazepines as BRD4 inhibitors and their preparation patent WO2014026997, 2014.
   Google Scholar
• Siegel S, Baeurle S, Cleve A, et al., inventors; Bayer Pharma AG, assignee. Preparation of bicyclo 2,3-benzodiazepines and spirocyclo 2,3-benzodiazepines as BRD4 inhibitors patent WO2014128067, 2014.
   Google Scholar
• Siegel S, Baeurle S, Cleve A, et al., inventors; Bayer Pharma Aktiengesellschaft, assignee. Preparation of 1-phenyl-3H-2,3-benzodiazepines and their use as bromodomain inhibitors patent WO2015121268, 2015.
   Google Scholar
• Siegel S, Baeurle S, Cleve A, et al., inventors; Bayer Pharma Aktiengesellschaft, assignee. Preparation of 9-substituted 2,3-benzodiazepines as bromodomain inhibitors patent WO2015121230, 2015.
   Google Scholar
• Siegel S, Cleve A, Haendler B, et al., inventors; Bayer Pharma Aktiengesellschaft, assignee. Preparation of 1-phenyl-4,5-dihydro-3H-2,3-benzodiazepine derivatives as bromodomain inhibitors patent WO2016062688, 2016.
   Google Scholar
• Fu Y, Zhang Y, Sun H. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins. Eur J Med Chem. 2021 Dec 15;226:113853. doi: 10.1016/j.ejmech.2021.113853
   PubMed Web of Science ®Google Scholar
• Petretich M, Demont EH, Grandi P. Domain-selective targeting of BET proteins in cancer and immunological diseases. Curr Opin Chem Biol. 2020 Aug;57:184–93. doi: 10.1016/j.cbpa.2020.02.003
   PubMed Web of Science ®Google Scholar
• Tomaselli D, Mautone N, Mai A, et al. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). Eur J Med Chem. 2020 Dec 1;207:112750.
   PubMed Web of Science ®Google Scholar
• Tomaselli D, Lucidi A, Rotili D, et al. Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med Res Rev. 2020 Jan;40(1):190–244.
   PubMed Web of Science ®Google Scholar